Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.46 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.44 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 5/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436646 | 0.91 | CCR2 (0.44) | IGF2BP2KCNK2KCNK10CCR2RXFP1 | |
| SCHEMBL7384811 | 0.86 | MAPK14 (0.51) | IGF2BP2KCNK2KCNK10CCR2RXFP1 | |
| SCHEMBL687475 | 0.85 | IGF2BP2 (0.58) | IGF2BP2KCNK2KCNK10RXFP1KCNQ3 | |
| SCHEMBL2995691 | 0.84 | CCR2 (0.58) | CCR2RXFP1POLB | |
| SCHEMBL5444022 | 0.83 | IGF2BP2 (0.49) | IGF2BP2KCNK2KCNK10GCGRATM | |
| SCHEMBL17295021 | 0.82 | IGF2BP2 (0.46) | IGF2BP2KCNK2KCNK10RXFP1KCNQ3 | |
| SCHEMBL7668964 | 0.81 | POLB (0.43) | IGF2BP2KCNK2KCNK10RXFP1KCNQ3 | |
| SCHEMBL27529466 | 0.80 | CCR2 (0.42) | IGF2BP2CCR2EPHX2POLB | |
| SCHEMBL4839187 | 0.80 | CCR2 (0.46) | CCR2RXFP1ALDH1A1POLB | |
| SCHEMBL27529465 | 0.80 | CCR2 (0.42) | IGF2BP2CCR2EPHX2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776884-B2 | Cyclic derivatives as modulators of chemokine receptors activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-17 | — | — | US | disclosed |
| US-20070073064-A1 | Method for producing aminopyrrolidine derivatives and intermediate compounds | TEIJIN PHARMA LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070073064-A1 | Method for producing aminopyrrolidine derivatives and intermediate compounds | TEIJIN PHARMA LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1483241-A4 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2006-12-13 | — | — | EP | disclosed |
| CN-1863769-A | Process for preparing aminopyrrolidine derivatives and intermediate compounds | TEIJIN PHARMA LTD (JP) | 2006-11-15 | — | — | CN | disclosed |
| US-7087604-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1676837-A1 | PROCESS FOR PRODUCING AMINOPYRROLIDINE DERIVATIVE AND INTERMEDIATE COMPOUND | Teijin Pharma Limited (JP) | 2006-07-05 | — | — | EP | disclosed |
| US-20060135503-A1 | Cyclic derivatives as modulators of chemokine receptors activity | CHERNEY ROBERT J | 2006-06-22 | — | — | US | disclosed |
| EP-1483241-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030216434-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-20 | — | — | US | disclosed |
| WO-2003075853-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135503-A1 | Cyclic derivatives as modulators of chemokine receptors activity | CCL11, CCR1, CCL2 | IGF2BP2 2608/4885KCNK2 3281/4885KCNK10 3128/4885 |
| US-20030216434-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCR1, CCL11, CXCR1 | IGF2BP2 2588/4885KCNK2 2932/4885KCNK10 2768/4885 |
| US-20070073064-A1 | Method for producing aminopyrrolidine derivatives and intermediate compounds | ACKR3, CCR2, CCR5 | IGF2BP2 2330/4885KCNK2 2018/4885KCNK10 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.